Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III randomized double-blind placebo-controlled study of Romiplostim N01 (QL0911) for chemotherapy-induced thrombocytopenia in patients with malignancy
CTR20242788Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of romiplostim in chemotherapy-induced thrombocytopenia (CIT), sponsored by Qilu Pharmaceutical. Started Oct 2024; status: active.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on CTR20242788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242788.